Daré Bioscience, Inc.
DAREDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
DARE Earnings Report
EPS Est: $-0.33 | FQ end 2026-06
DARE-BV1clindamycin phosphate vaginal gel, 2%
Bacterial Vaginosis
Tamoxifen
Vulvar Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DARE-BV1clindamycin phosphate vaginal gel, 2% | Phase 3 | Bacterial Vaginosis | - | - |
Tamoxifen | Phase 2 | Vulvar Atrophy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Daré Bioscience, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Daré Bioscience, Inc.'s (DARE) pipeline across Phase 3, Phase 2. Its lead program is DARE-BV1clindamycin phosphate vaginal gel, 2% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Daré Bioscience, Inc.'s next FDA catalyst?→
Daré Bioscience, Inc.'s (DARE) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DARE biotech catalysts?→
Add DARE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daré Bioscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.